2022 World Conference on Lung Cancer (ePosters)-EP08.01-099. Activity of aPD1-MSLN-CART Cells against Metastatic Lung Cancer in a Phase 1 Trial

Pdf Summary

A Phase 1 trial conducted by Xiaorong Dong and her team at Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China, evaluated the safety and efficacy of aPD1-MSLN-CART cells in patients with chemotherapy-refractory metastatic lung cancer. Mesothelin (MSLN) was found to be highly expressed in multiple solid tumors, including lung cancer. The researchers engineered autocrine PD-1 nano antibodies MSLN-CAR-T cells, which targeted MSLN positive tumor cells and secreted PD1 antibodies, thus employing a dual antitumor immune mechanism.<br /><br />Out of the 40 patients screened, 5 were successfully enrolled in the study. Two patients completed 1 cycle of aPD1-MSLN-CART cell infusion, while 2 patients completed 2 cycles. One patient withdrew before transfusion. None of the patients experienced cytokine release syndrome or neurologic symptoms, and there were no dose limiting toxicities. The results showed that 1 patient had a partial response, 2 patients had stable disease, and 1 patient had disease progression.<br /><br />The study also observed transient CAR expression in the patients' blood after infusion, leading to changes in CD3CD4CAR-T cells, CD3CD8CAR-T cells, and cytokine levels including IL-6, IL-10, INF-γ, and TNF-α. Figure 1 depicts CT images of a patient after 2 cycles of CAR-T cell transfusion, showing a positive response.<br /><br />In conclusion, the findings from this Phase 1 trial suggest that aPD1-MSLN-CART cells have the potential for anti-tumor activity in patients with chemotherapy-refractory metastatic lung cancer. Further research and clinical trials are needed to validate these results and explore the effectiveness and safety of this therapy in a larger patient population.

Asset Subtitle

Xiaorong Dong

Meta Tag

Speaker Xiaorong Dong

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Phase 1 trial

Xiaorong Dong

Cancer Center

Union Hospital

Tongji Medical College

Huazhong University of Science and Technology

aPD1-MSLN-CART cells

metastatic lung cancer

chemotherapy-refractory

mesothelin